Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on March 15, 2016, covering events occurring on March 11, 2016. The filing addresses a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance matters and does not contain financial performance data.
Material Changes
The Board of Directors reduced its size from nine (9) members to seven (7) members. Mr. George A. Oram, the least tenured member, resigned effective March 11, 2016, at the request of the Board to assist in this reduction.
Outlook, Risks, and Management Commentary
Management stated that Mr. Oram's resignation was not due to any disagreement with the Company regarding its operations, policies, or practices. The filing does not contain forward-looking guidance, risk factors, or discussion of unusual items.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the resignation.
- Confirm that no other undisclosed disagreements exist between the departing director and the Company.
- Review subsequent filings for the appointment of any new directors to fill the vacancy.